The Animal Imaging Core provides a wide array of non-invasive, high resolution quantitative imaging-based capabilities for metabolic and genetic characterization of tumors and their microenvironment. Among the critical scientific applications of small-animal imaging by MSKCC investigators are: phenotypic screening of tumor incidence, progression and therapy-induced regression in xenograft models and transgenic/knock-out models;assessment of trafficking of cancer cells, stem cells, and immune effector cells in vivo;evaluation of trans-gene expression, development, testing, and validation of targeted therapies (i.e. pharmacodynamics); and detection and localization of tumor hypoxia and re-oxygenation. These capabilities are broadly applicable to the fundamental mission of the Center in areas such as molecular imaging, assessment of therapeutic response, and drug development. The services provided by the Animal Imaging Core has supported the research of 65 investigators in the past year. During the past grant period the work of the Core has contributed to 370 publications of researchers from 9 research programs. As part of a major expansion and modernization of MSKCC's infrastructure, the Imaging Core has been consolidated and re-located to the Zuckerman Research Center's vivarium. This area provides enhanced biosecurity and functionality and houses the R4 and Focus 120 microPET, ivis 100 opfical imaging system, microCATII, microCT, NanoSPECT/CT Plus, SPECT-CT, Maestro, FMT 2500 near-Infrared fluorescence tomography system, and Vevo 2100 ultrasound system. The existing Ivis 100 optical imaging system remains at the Rockefeller Research Laboratory, supporting investigators In that building. A new high precision microirradiator, X-RAD, for rodent tumors and other structures was installed in 2012. The Core's 4.7T and 7.0T Brucker USR systems have also been moved to the Vivarium. The Core has provided critical support for the development and characterization of mouse models for human cancer. For example, models for glioma driven by PDGF-B signaling and anaplastic thyroid tumors driven by inducible mutant BRAF have been extensively characterized and examined for therapeutic responses using the imaging resources of the Core.

Public Health Relevance

The Animal Imaging Core Provides non-invasive, high resolution quantitative imaging-based capabilities for metabolic and genetic characterization of tumors and their microenvironment. These capabilities which are broadly applicable to the fundamental mission of the Center in such diverse and important space areas as molecular imaging, assessment of treatment response, and drug development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-48
Application #
8933523
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2014-01-01
Project End
2018-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
48
Fiscal Year
2014
Total Cost
$247,784
Indirect Cost
$108,344
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Lichtenthal, Wendy G; Maciejewski, Paul K; Craig Demirjian, Caraline et al. (2018) Evidence of the clinical utility of a prolonged grief disorder diagnosis. World Psychiatry 17:364-365
Cottrell, T R; Thompson, E D; Forde, P M et al. (2018) Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol 29:1853-1860
Pereira, PatrĂ­cia M R; Sharma, Sai Kiran; Carter, Lukas M et al. (2018) Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat Commun 9:5137
Mano, Roy; Di Natale, Renzo; Sheinfeld, Joel (2018) Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer. Urol Oncol :
Zhu, Guo; Benayed, Ryma; Ho, Caleb et al. (2018) Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Mod Pathol :
Gollub, Marc J; Hotker, Andreas M; Woo, Kaitlin M et al. (2018) Quantitating whole lesion tumor biology in rectal cancer MRI: taking a lesson from FDG-PET tumor metrics. Abdom Radiol (NY) 43:1575-1582
Rapp, Moritz; Wiedemann, Gabriela M; Sun, Joseph C (2018) Memory responses of innate lymphocytes and parallels with T cells. Semin Immunopathol 40:343-355
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164
Zabor, Emily C; Furberg, Helena; Lee, Byron et al. (2018) Long-Term Renal Function Recovery following Radical Nephrectomy for Kidney Cancer: Results from a Multicenter Confirmatory Study. J Urol 199:921-926
Bakhoum, Samuel F; Ngo, Bryan; Laughney, Ashley M et al. (2018) Chromosomal instability drives metastasis through a cytosolic DNA response. Nature 553:467-472

Showing the most recent 10 out of 8799 publications